OS10.6 Infigratinib (BGJ398) in patients with recurrent gliomas with fibroblast growth factor receptor (FGFR) alterations: a multicenter phase II study
Andrew B. Lassman(Columbia University), Patrick Roth(University Hospital of Zurich), C Belda-Iniesta(Hospital Universitario HM Sanchinarro), Patrick Y. Wen(Dana-Farber Cancer Institute), Jeffrey J. Raizer(Northwestern University), Filip De Vos(University Medical Center Utrecht), Y. Ye(QED Technologies (United States)), Vinay K. Puduvalli(The University of Texas MD Anderson Cancer Center), Keith Steward(QED Technologies (United States)), Timothy F. Cloughesy(University of California, Los Angeles), Juan Manuel Sepúlveda-Sánchez(Hospital Universitario 12 De Octubre), Susan Moran(QED Technologies (United States)), Nicholas Butowski(University of California, San Francisco), Paul M. Clément(Universitair Ziekenhuis Leuven), Morris D. Groves(Texas Oncology), Juan Gil-Gil(Duran i Reynals Hospital)
Cited by 11
Related Papers
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
|Nature|2018|1.5k
Molecular Determinants of the Response of Glioblastomas to EGFR Kinase Inhibitors
|New England Journal of Medicine|2005|1.4k